eyecro COO Gives Talk at ARVO

When a preclinical efficacy study wraps up at EyeCRO, ocular tissues move directly from our animal facility to our bioanalytical lab. No third-party handoffs. No waiting in an external lab’s queue. Sponsors receive a single integrated dataset covering both in-life endpoints and bioanalytical quantitation from the team that ran the entire study. LC-MS/MS Quantitation Our…

Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities.  “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…

Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more

Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.

We are proud to announce a significant breakthrough in ophthalmic care: our innovative MiDROPS® technology has been validated for safety and efficacy in its first clinical application. Data from the technology’s first clinical application is being presented at the 96th meeting of the Association for Research in Vision and Ophthalmology in Seattle, WA. Read the…

EyeCRO will be attending the 2026 ARVO Annual Meeting in Denver, Colorado, May 3-7. ARVO brings together over 11,000 eye and vision researchers from 75 countries, and it remains the most important meeting in our field for sharing new findings and building collaborations. This year’s theme focuses on how innovative vision research is driving the…